ISV - Sector: Healthcare --- Industry: Biotechnology & Drugs

[Melf Elf]

2.70?? Wow, the little devil inside me started getting greedy when I read your post.

Bocasva,

Sorry, I didn't mean to tempt your greed devil.     Hee hee hee.   

My greed devil is annoyed that they didn't fill me at back 1.57.   

I'd have a paper gain of nearly 15% here.  Curses! 

If volume starts incrementing over the next sessions 2.70 is very realistic.

Volume was just "okay" on the breakout.  Yesterday was an improvement to a little better than 2 times ADV, so that's good.  Blocks of 5,000 and 10,000 were able to go off with the added liquidity, so it attracts more buyers.

That's the problem that I had getting filled at 1.57 the other day.  No volume to speak of, so they moved the BID...ASK away from me.

My original target had been 1.96 but I just have to let the chart do the talking.

You will have a very nice paper gain at that price, so you might want to stick with your plan and take some there, to protect your profits, just in case it Double Tops near 1.97, and the 2.06 target doesn't get MADE, let alone the 2.70.  You never know...

I do think that if there's even a hint of good news from the company, the technical traders will have to like this chart, and will step in and buy a breakout.  They did a little bit of that the past few days, on the breakout of the  Bullish Inverse H&S.

Pretty chart.  A breakout above 1.97 on volume would be very pretty.

Continued good luck! 

[Melf Elf]

Bocasva,

Some nice buying interest coming in. 

13,500 shares at 1.85...15,300 shares at 1.87...

The run rate on volume is close to 2 times average daily. 

[Melf Elf]

Bocasva,

Steadily creeping back toward the 1.97 high...

You've got a very nice trade going here.

How's your Greed Devil doing?   

[bocasva]

Bocasva,

Steadily creeping back toward the 1.97 high...

You've got a very nice trade going here.

How's your Greed Devil doing?   

Thanks Melf Elf.
Let's hope ISV keeps behaving nice and hits our targets.
I went to church today to try to keep that little devil in control, hehehehe.

[bocasva]

Today's shakeout should help consolidate ISV to continue its upward movement.

[bocasva]

Today's shakeout should help consolidate ISV to continue its upward movement.

LOL, talk about shakeouts, I was shakenout at 1.68(luckily).
WOW, what  a day; it went from 1.87 to 1.32

[Melf Elf]

LOL, talk about shakeouts, I was shakenout at 1.68(luckily).
WOW, what  a day; it went from 1.87 to 1.32

Bocasva,

Whoa!  You still have a nice gain at 1.68, though.  Good going.  Applause.

[livermore]

Setravis,

excellent call on ISV where do you see it going now?

[la-onda]

up to 1.9$ AH 
why?
InSite Vision Announces Patent Agreement With Pfizer
Thursday February 15, 4:00 pm ET

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV - News) -- an ophthalmic therapeutics, diagnostics and drug delivery company, today announced that it has entered into a worldwide, exclusive royalty bearing licensing agreement with Pfizer Inc. (NYSE:PFE - News) under Pfizer's Patent family titled "Method of Treating Eye Infections with Azithromycin". Pfizer's granting of this license will enhance the position and marketability of InSite's AzaSite franchise.

S. Kumar Chandrasekaran, Ph.D., InSite Vision's chief executive officer stated, "The execution of the Pfizer license represents a significant milestone in the development of InSite Vision's AzaSite franchise. Combined with our existing azithromycin and DuraSite drug-delivery patents, this license further broadens InSite Vision's global patent portfolio."

Under the terms of the agreement, Pfizer will grant InSite a worldwide, exclusive license, including the right to sublicense, to U.S. and all foreign counterparts patents on the parent case titled "Method of Treating Eye Infections with Azithromycin" and patent applications together with any reissues, extensions, or supplementary protection certificates of any of the foregoing for use in connection with InSite's AzaSite franchise products.

[Melf Elf]

up to 1.9$ AH 
why?
InSite Vision Announces Patent Agreement With Pfizer
Thursday February 15, 4:00 pm ET

Oliver,

1.90305 is the top of an 8-Month Symmetrical Triangle (pattern in black) for today, February 16, so a print of 1.91 is a technical breakout, which would put 2.67 IN PLAY (math for the target is at the upper right on the chart).

Within the Symmetrical Triangle, ISV formed TWO Inverse H&S patterns (one in blue, the other in purple).  Both broke out; both were failures.  They now are nested within the large Symmetrical Triangle, so ISV is packing some punch, technically, if it can break out on the print of 1.91. 

The prior highs of 1.97 and 1.93 obviously need to get taken out to the upside, but if volume comes in, this could be a "Gap and Go" opening, rather than a "Gap To Crap" since it's a technical breakout of a strong 8-month base.

Good luck!

[setravis]

Shorts should be gone.......
Could be a nice little base put in here @ the $1.40 area.
InSite's topical anti-infective product currently under NDA review by the FDA for the treatment of bacterial conjunctivitis; commonly referred to as "pink eye". The global market opportunity for topical, ocular anti-infective products currently exceeds one billion dollars.

52wk Range: 1.20 - 2.70
Volume: 665,400
Avg Vol (3m): 282,246

Technicals
Close Above the 13-day MA
Percentage Gainer

RS Rating: 24 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 05/10/2007
Last Analyst Rating: Buy

[setravis]

ISV has several caveats of concern but the volume action is triggering a buy signal.
Maintaining support,
Closed above the 13/50/200-day MA's
On the 6 month chart looks to have placed a Double Bottom.......
On the 1 year chart the Symmetrical Triangle "coil look"...looking for bounce !



Volume: 2,214,700
Avg Vol (3m): 348,160
Market Cap: 159.49M

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
12.90%above 13-day MA
11.24%above 50-day MA
RS Rating: 81 

Fundamentals
Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 08/13/2007
Last Analyst Rating: Buy

Below are the 6 month and 1 year charts.......

[fill_the_gap]

Hi,

Buying large percentage of portfolio into ISV right now.

The call should bode very well.

Looking for 30 cent move near term, imo.

[setravis]

• Q2 2007 InSite Vision Incorporated Earnings Release - Time Not Supplied
CCBN (Wed 7:07am


52wk Range: 1.24 - 1.97
Volume: 395,400
Avg Vol (3m): 337,618

Technicals
Close Above the 13-day MA .......

Last Price Quote is:
2.43%above 13-day MA
-2.68%below 50-day MA
RS Rating: 20 

Fundamentals
Earnings Expected on Aug 8

Key Data:
Market Cap (M): $30.56 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/13/2007
Last Analyst Rating: Buy

Below are the 6 month , 2 year and 3 year charts.......

[fill_the_gap]

Call is 5:00 EST

Press Release Source: InSite Vision Incorporated


InSite Vision Reports Second Quarter 2007 Financial Results
Wednesday August 8, 4:05 pm ET


ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (AMEX:ISV - News), an ophthalmic therapeutics, diagnostics and drug delivery company, today reported financial results for the three months ended June 30, 2007.
Net income for the second quarter ended June 30, 2007 is $2.2 million, or $0.02 per share, compared to a net loss of $5.1 million or $ 0.06 per share for the second quarter 2006. The difference was attributed mainly to the recognition of deferred revenue related to the licensing of AzaSite(TM) (1% azithromycin ophthalmic solution) to Inspire Pharmaceuticals and the milestone payment, received following the signing of the agreement and approval of AzaSite(TM) by the FDA on April 27, 2007.

Research and development (R&D) expenses were $2.1 million for the second quarter 2007, compared to $2.8 million in the same quarter in 2006.

Selling, general and administrative (SG&A) expenses increased to $2.1 million in the second quarter 2007, compared to $1.7 million in the same quarter in 2006.

InSite Vision had cash and cash equivalents of $18.9 million at June 30, 2007, compared to $986,000 at December 31, 2006.

For the six months ended June 30, 2007, the Company reported a net loss of $416,000 or, $0.00 per share compared to a net loss of $10.5 million or $0.12 per share for the six months ended June 30, 2006.

Research and development expenses decreased to $3.9 million for the first six months of 2007, compared to $6.0 million in the first six months of 2006. This was due largely to a decrease in external service expenses, which had been primarily related to the AzaSite clinical trials, preparation of the related NDA and the filing fee in 2006.

Selling, general and administrative expenses increased to $3.7 million for the first six months of 2007 compared to $3.4 million in the first six months of 2006.

"With the approval and imminent launch of AzaSite(TM), InSite Vision is at a pivotal point in our business. By leveraging our DuraSite technology and the revenue from AzaSite commercialization, we believe that we have technological and financial capabilities to expand and advance our product pipeline and lead us to profitability and growth," said S. Kumar Chandrasekaran, PhD, chief executive officer, InSite Vision